Table 1.
The demographic and clinical findings at renal biopsy by LN class.
| Total (N = 244) |
Class II (N = 7) |
Class III (N = 38) |
Class IVG (N = 117) |
Class IVS (N = 39) |
Class V (N = 43) |
|
|---|---|---|---|---|---|---|
| Female (n, %) | 219 (89.8%) | 5 (71.4%) | 35 (92.1%) | 106 (90.6%) | 34 (87.2%) | 39 (90.7%) |
| Age (years) | 34 ± 12 | 42 ± 9.8 | 34.7 ± 13.2 | 32 ± 11.4† | 33 ± 11.1 | 38.6 ± 12.5 |
| Current immunosuppressive agents (n, %) | ||||||
| Prednisolone | 226 (92.6%) | 6 (85.7%) | 37 (97.4%) | 104 (88.9%) | 38 (97.4%) | 41 (95.3%) |
| Azathioprine | 72 (29.5%) | 2 (28.6%) | 9 (23.7%) | 31 (26.5%) | 14 (35.9%) | 16 (37.2%) |
| Cyclophosphamide | 85 (34.8%) | 2 (28.6%) | 14 (36.8%) | 40 (34.2%) | 13 (33.3%) | 16 (37.2%) |
| Mycophenolate mofetil | 39 (16%) | 1 (14.3%) | 8 (21.1%) | 19 (16.2%) | 7 (17.9%) | 4 (9.3%) |
| Current antihypertensive agents (n, %) | ||||||
| ACEI/ARB | 102 (41.8%) | 4 (57.1%) | 12 (31.6%) | 45 (38.5%) | 19 (48.7%) | 22 (51.2%) |
| CCB | 59 (24.2%) | 3 (42.9%) | 3 (7.9%)* | 36 (30.8%) | 9 (23.1%) | 8 (18.6%) |
| BB | 15 (6.1%) | — | — | 8 (6.8%) | 5 (12.8%) | 2 (4.7%) |
| Extrarenal manifestation (n, %) | ||||||
| Arthritis | 134 (54.9%) | 2 (28.6%) | 28 (73.7%) | 59 (50.4%) | 20 (51.3%) | 25 (58.1%) |
| Malar rash | 112 (45.9%) | 2 (28.6%) | 16 (42.1%) | 57 (48.7%) | 20 (51.3%) | 17 (39.5%) |
| Discoid rash | 60 (24.6%) | 1 (14.3%) | 6 (15.8%) | 28 (23.9%) | 10 (25.6%) | 15 (34.9%) |
| Photosensitivity rash | 45 (18.4%) | 1 (14.3%) | 7 (18.4%) | 20 (17.1%) | 8 (20.5%) | 9 (20.9%) |
| Oral ulcer | 66 (27%) | — | 11 (28.9%) | 39 (33.3%) | 6 (15.4%) | 10 (23.3%) |
| AIHA | 79 (32.4%) | — | 13 (34.2%) | 45 (38.5%) | 10 (25.6%) | 11 (25.6%) |
| Leukopenia | 86 (35.2%) | 1 (14.3%) | 18 (47.4%) | 44 (37.6%) | 11 (28.2%) | 12 (27.9%) |
| Thrombocytopenia | 64 (26.2%) | 1 (14.3%) | 8 (21.1%) | 30 (25.6%) | 14 (35.9%) | 11 (25.6%) |
| Serositis | 50 (20.5%) | — | 6 (15.8%) | 32 (27.6%) | 8 (20.5%) | 4 (9.3%) |
| CNS | 11 (4.5%) | — | — | 7 (6%) | — | 4 (9.3%) |
Data are mean ± SD, median with interquartile range and percentages; † P < 0.05 versus class V and * P < 0.05 versus class II. ACEI: angiotensin converting enzyme inhibitor, AIHA: autoimmune hemolytic anemia, ARB: angiotensin type 1 receptor blocker, BB: beta-blockers, CCB: calcium channel blocker, CNS: central nervous system.